Compounds / Thymosin β4

Thymosin β4

Tβ4 · TB4 full protein

Thymosin β4 has 18 registered human trials on record. It is marketed for 4 different uses.

In short

  • 18 registered human trials exist for Thymosin β4.
  • No registered trial lists tissue repair, hair growth or cardiac recovery as a studied condition.
  • Thymosin β4 is not FDA-approved for any use.
  • What has actually been studied: atherosclerotic cardiovascular diseases, endothelial dysfunction.
  • 3 studies are open to new participants, so this may change.
  • Last checked against ClinicalTrials.gov on 2026-07-27.
18
Registered human trials
3
Recruiting or running
No
FDA approved
Pre
P1
P2
P3
Furthest stage reached

What it's sold for

  • Tissue repair
  • Wound healing
  • Hair growth
  • Cardiac recovery

What has actually been tested

  • Acute Myocardial Infarction
  • Dry Eye
  • Dry Eye Syndrome
  • Healthy
  • Acute Myocardial Infarction (AMI)
  • Acute Myocardial Infarction of Anterior Wall
  • Acute Myocardial Infarction of Left Ventricle
  • Acute Myocardial Infarction With ST Elevation

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Not listed Tissue repair
Studied Wound healing
Not listed Hair growth
Not listed Cardiac recovery

Every trial on record

Every registered human study we can find for Thymosin β4. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial IDTitleConditionPhaseStatusEnrolled
NCT07487363 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction Phase 2 Recruiting now 80
NCT05555589 Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 Neurotrophic Keratopathy Phase 3 Recruiting now 70
NCT07586865 Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall Phase 2 Not yet recruiting 189
NCT00382174 Study of Thymosin Beta 4 in Patients With Pressure Ulcers Pressure Ulcers Phase 2 Completed 72
NCT02974907 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 Dry Eye Syndrome Phase 3 Completed 601
NCT04555824 A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers Healthy Phase 1 Completed 54
NCT05984134 Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction Acute Myocardial Infarction Phase 2 Completed 90
NCT04555850 A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers Healthy Phase 1 Completed 30
NCT00832091 Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers Venous Stasis Ulcers Phase 2 Completed 72
NCT03937882 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 Dry Eye Syndromes, Dry Eye Phase 3 Completed 700
NCT02597803 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 Dry Eye Syndrome Phase 3 Completed 317
NCT05485818 Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction Acute Myocardial Infarction Phase 2 Completed 62
NCT01387347 Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye Dry Eye Syndrome, Dry Eye Phase 2 Completed 72
NCT01393132 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye Dry Eye, Sjogren's Syndrome Phase 2 Completed 9
NCT00743769 A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers Myocardial Infarction, Myocardial Ischemia Phase 1 Withdrawn before enrolling 0 — nobody enrolled
NCT01311518 A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction Acute Myocardial Infarction, ST Elevation Myocardial Infarction Phase 2 Withdrawn before enrolling 0 — nobody enrolled
NCT00311766 A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa Epidermolysis Bullosa Phase 2 Stopped early 30
NCT00598871 A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds Diabetes Phase 2 Stopped early 12
—Read this
A trial count is not a verdict
These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Common questions about Thymosin β4

How many human trials does Thymosin β4 have?

18. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Thymosin β4 FDA approved?

No. Thymosin β4 is not approved by the FDA for any indication. Compounded or "research use only" preparations are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality.

What is Thymosin β4 actually being tested for?

Registered studies cover: atherosclerotic cardiovascular diseases, endothelial dysfunction, neurotrophic keratopathy. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.

Get told when this changes

One email a week: what moved in the research, and which claims the record doesn't support. Free, and you can leave in one click.